IFRX Strangle Strategy
IFRX (InflaRx N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder.
IFRX (InflaRx N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $296.1M, a beta of 2.50 versus the broader market, a 52-week range of 0.779-2.949, average daily share volume of 1.8M, a public-listing history dating back to 2017, approximately 65 full-time employees. These structural characteristics shape how IFRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.50 indicates IFRX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on IFRX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
IFRX snapshot
As of August 14, 2026, spot at $2.01, ATM IV 42.10%, IV rank 5.33%, expected move 12.07%. The strangle on IFRX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on IFRX specifically: IFRX IV at 42.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a IFRX strangle, with a market-implied 1-standard-deviation move of approximately 12.07% (roughly $0.24 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IFRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IFRX should anchor to the underlying notional of $2.01 per share and to the trader's directional view on IFRX stock.
IFRX strangle setup
The IFRX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IFRX at $2.01 on that close, the first option leg uses a $2.11 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IFRX chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IFRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.11 | N/A |
| Buy 1 | Put | $1.91 | N/A |
IFRX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IFRX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IFRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on IFRX
Strangles on IFRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IFRX chain.
IFRX thesis for this strangle
The market-implied 1-standard-deviation range for IFRX extends from approximately $1.77 on the downside to $2.25 on the upside. A IFRX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IFRX IV rank near 5.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IFRX at 42.10%. As a Healthcare name, IFRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IFRX-specific events.
IFRX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IFRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IFRX alongside the broader basket even when IFRX-specific fundamentals are unchanged. Always rebuild the position from current IFRX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IFRX?
- A strangle on IFRX is the strangle strategy applied to IFRX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IFRX stock at $2.01 on the most recent close, the strikes shown on this page are snapped to the nearest listed IFRX chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are IFRX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IFRX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 42.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IFRX strangle?
- The breakeven for the IFRX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IFRX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.07%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IFRX?
- Strangles on IFRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IFRX chain.
- How does current IFRX implied volatility affect this strangle?
- IFRX ATM IV is at 42.10% with IV rank near 5.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.